Skip to main content
All lobbying filings

AMERICAN UROLOGICAL ASSOCIATION

AMERICAN UROLOGICAL ASSOCIATION filed a Q2 report for AMERICAN UROLOGICAL ASSOCIATION on July 18, 2025.

Lobbying for AMERICAN UROLOGICAL ASSOCIATION

All filings by AMERICAN UROLOGICAL ASSOCIATION · Everything AMERICAN UROLOGICAL ASSOCIATION has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 18, 2025
Expenses
$62,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Maryland

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Reduce administrative burdens (e.g., prior authorization, step therapy, and medical malpractice) that negatively impact the practice of medicine and patient care; Advocate to ensure access to telehealth services as an alternative health care delivery model in urology to address access to care and health care equity; Enhance healthcare outcomes by ensuring equitable access to a full range of treatment options for all urologic conditions, regardless of patient demographics, geography, or financial status; Advocate for the full spectrum of prostate cancer care including, research, US Preventive Services Task Force (USPSTF) reforms, PSA screenings, and treatments for all patients; Address the needs of the urological workforce to protect against physician burnout for the continued longevity and expansion of the profession; Promote and protect funding for urologic research, including disparities in urologic care and patient access; Preserve the appropriate use of and payment for in-office ancillary services exception; Support policies to protect physician interests in the utilization of digital health technologies, including electronic health records and artificial intelligence, which impact the practice of urology; Encourage drug pricing and supply chain policies that ensure urologists ability to provide patient access to all pharmaceuticals or therapies.

Advocate for permanent reforms for Medicare physician payment and reimbursement policies that provide stability for all practice models.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem